Assoc. Prof.Cengiz Dibekoğlu, MD

General Surgeon

Laparoscopic · Robotic · Oncologic Surgery

Conditions/Breast surgery

Breast

Breast Disease

Cysts, cancer, diagnosis, genetics, and multidisciplinary care

Imaging + biopsy + tumor biology (ER/PR/HER2) define the real pathway — not fear alone.

Breast care includes benign cysts and fibroadenomas as well as cancer diagnosis, surgery, and systemic planning. Triple assessment — exam, imaging, and pathology — prevents both missed cancers and unnecessary mastectomy for fear. Tumor biology (ER/PR/HER2/Ki-67) shapes chemotherapy, endocrine therapy, and anti-HER2 options. Genetic testing frameworks (including offering BRCA1/2 testing to newly diagnosed patients ≤65, individualized above 65) belong in the same conversation as surgery choice. Neoadjuvant therapy can reshape breast and axillary plans — the first sketch is not always the final map.

Breast Disease · educational illustration

Educational figures

Tap a figure to enlarge. These English illustrations mirror the Turkish hub gallery for this condition.

  • Diagnosis
  • Cancer
  • Treatment
  • Multidisciplinary

  • Triple assessment

    Exam, imaging, and pathology together.

  • Biology matters

    ER/PR/HER2/Ki-67 shape systemic therapy.

  • Genetics

    BRCA offers follow age and risk features.

  • Tumor board

    Oncology partners guide multimodal care.

Key points for patients

  • Genetic testing frame
    Tap for details · key note inside

    Newly diagnosed patients ≤65 are generally offered BRCA1/2 testing; above 65, testing is individualized (e.g., triple-negative, male breast cancer, bilateral disease, strong family history).

  • Not every lump is cancer
    Tap for details

    Cysts and fibroadenomas are common — characterization prevents overtreatment while still catching malignancy.

  • Surgery is not a slogan
    Tap for details

    Breast-conserving surgery and mastectomy are chosen by tumor size, biology, genetics, reconstruction wishes, and oncologic margins — not by “safer equals more tissue removed.”

  • Neoadjuvant can redraw the map
    Tap for details

    After systemic therapy, breast and axillary plans are reassessed. The initial recommendation is a starting point, not a locked vow.

  • Multidisciplinary care
    Tap for details

    Surgery, medical oncology, radiation, genetics, and reconstruction share decisions so sequencing serves the whole pathway.

Patient journey

In this hub — follow the pathway step by step. Full Turkish illustrated pages remain linked from each chapter.

Breast surgery4 chapters

Appointment / info

Bring mammogram/ultrasound/MRI CDs and pathology — biology and imaging decide more than fear alone.

+90 542 725 50 70WhatsAppTumor boardFull Turkish hub →

Educational information only; not a substitute for clinical evaluation.

Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · English patient-education hub.

AppointmentWhatsAppMessageTumor boardRequest